Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Ayub Med Coll Abbottabad ; 32(3): 323-326, 2020.
Article in English | MEDLINE | ID: mdl-32829544

ABSTRACT

BACKGROUND: This study was conducted to see the frequency of hormone receptors and Her-2/Neu positivity in different histology in breast cancer patients. METHODS: It was a cross-sectional study conducted at the Department of Medical Oncology, Jinnah Postgraduate Medical Centre from June 2018- March 2019. Total 373 patients of age 22-81 years of which 360 female and 13 males, with histopathological proven diagnosis of breast cancer were included in the study using non-probability consecutive sampling technique. The immunohistochemistry (IHC) was performed on biopsy sample for the status of PR, ER and HER-2/Neu and the confirmation of Her-2/Neu was done by Fluorescent In situ Hybridization (FISH) technique if HER-2/Neu was equivocal by IHC testing. Information regarding demographics, family history, histology, grade, stage, metastatic site and other histopathological parameters were noted on predesigned proforma by the researcher. SPSS-23 was used to analyse data. RESULTS: Total of 373 patients were included in the study. The mean patient age was 45.34±12.28 years. ER, PR, Her 2 Neu (IHC) & Her 2 Neu (FISH) were found positive in 206 (55.2%), 182 (48.8%), 121 (32.4%) & 23 (6.2%) patients, respectively. The histology with PR receptor & grade of tumour with ER & PR receptor showed statistical significance (p<0.05). CONCLUSIONS: ER, PR & HER-2/NEU expressions in breast cancer vary among different population and it is very important to find out the frequency among different histopathological types as it is of predictive and prognostic value. So, it is recommended to look for these markers and treat them accordingly.


Subject(s)
Breast Neoplasms , Receptor, ErbB-2/analysis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Adult , Aged , Aged, 80 and over , Breast Neoplasms/chemistry , Breast Neoplasms/epidemiology , Breast Neoplasms/pathology , Female , Humans , Immunohistochemistry , Middle Aged , Young Adult
2.
J Ayub Med Coll Abbottabad ; 32(1): 73-77, 2020.
Article in English | MEDLINE | ID: mdl-32468760

ABSTRACT

BACKGROUND: This study was conducted to determine the frequency of amenorrhea after chemotherapy among breast cancer patients". METHODS: Total 201 premenopausal females (having menstruation during the past 6 months at the time of diagnosis) of age 15-45 years and had confirmed diagnosis of breast cancer requiring chemotherapy were included in the study using non-probability consecutive sampling technique. Amenorrhea within 6 months after the completion of chemotherapy was labelled as chemotherapy induced amenorrhea. Data was entered and analysed using SPSS-23. RESULTS: The mean age of the patients was reported as 37.06±5.68 years. Majority of the females were married (86.6%) & multigravida (81.1%). Most of the patients (23.9%) received neoadjuvant chemotherapy followed by surgery and radiotherapy. A total of 129 patients received Adriamycin plus cyclophosphamide followed by paclitaxel as chemotherapy regimen. Out of 201 females, 184 (91.5%) experienced amenorrhea after start or completion of chemotherapy. CONCLUSIONS: The frequency of CIA was very high among breast cancer patients in our study, long term follow-up is needed to see input of CIA on future fertility.


Subject(s)
Amenorrhea , Antineoplastic Agents , Breast Neoplasms/drug therapy , Adult , Amenorrhea/chemically induced , Amenorrhea/epidemiology , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Female , Humans , Premenopause
SELECTION OF CITATIONS
SEARCH DETAIL
...